| Name | Title | Contact Details |
|---|---|---|
Richard Lewis |
Vice President of Sales | Profile |
Genna Burton |
Associate Director, Consumer Marketing | Profile |
Prem Ramiya |
Senior Vice President, Manufacturing and Supply Chain | Profile |
Caroline Hanover |
Vice President, HRBP | Profile |
Karen Frank |
Director, Human Resources | Profile |
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. TYRA is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. TYRA is advancing multiple product candidates toward the clinic including its lead product candidate TYRA-300, an FGFR3 inhibitor with an initial focus on patients with bladder cancer, and TYRA-200, an FGFR2 inhibitor with an initial focus on patients with intrahepatic cholangiocarcinoma who have developed drug resistance mutations from existing FGFR inhibitors.
Champions Oncology is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clinical Trials Services is a Lancaster, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Intrexon Corporation is a privately held synthetic biology company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science.
Alvine Pharmaceuticals is a San Carlos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.